Results 341 to 350 of about 869,856 (392)

Engineering Adenine Deaminase TadA for Precise and PAM‐Flexible Point Mutagenesis and Gradient‐Tuning Endogenous Protein Design

open access: yesAdvanced Science, EarlyView.
Base editing enables precise nucleotide substitutions but limited by bystander editing. This study engineers plant base editors by fusing optimized TadA variants with PAM‐flexible SpRY nickase, enabling A‐to‐G, C‐to‐T, and dual‐base conversions in a highly condensed window (≤3 nucleotides). Additionally, TadDBE (TadA Dual‐Base Editor)‐mediated directed
Kangli Sun   +14 more
wiley   +1 more source

EGFR‐TKIs Induced DPP4 Drives Metabolic Reprogramming of Persister Cells in Lung Cancer

open access: yesAdvanced Science, EarlyView.
Drug‐tolerant persister (DTP) cells emerge early during EGFR‐TKI treatment, preceding the development of acquired resistance. Elevated DPP4 in DTP cells drives metabolic reprogramming and antioxidant adaptation, promoting cell survival under drug pressure.
Yuanzhou Zhang   +7 more
wiley   +1 more source

Synthesis of Nucleoside Derivatives by Biomimetic Ester Migration. [PDF]

open access: yesChembiochem
Kurrle NJ   +8 more
europepmc   +1 more source

A Pump‐Free, Hydraulic‐Amplification Oscillatory Microfluidic Device for Continuous Particle and Cell Manipulation

open access: yesAdvanced Science, EarlyView.
This study demonstrates a pump‐free, hydraulic‐amplification oscillatory microfluidic device, which generates oscillatory flows by deforming flexible microchannels through reciprocating finger pressing. The mechanism of elasto‐inertial focusing in the oscillatory flows is revealed, and early detection of drug‐treated platelet aggregates and rapid cell ...
Yong Liu   +3 more
wiley   +1 more source

AI‐Driven De Novo Design of Ultra Long‐Acting GLP‐1 Receptor Agonists

open access: yesAdvanced Science, EarlyView.
De novo GLP‐1RAs can be computationally designed to exhibit extended half‐life and superior efficacy compared to Semaglutide. Abstract Peptide drugs have revolutionized modern therapeutics, offering novel treatment avenues for various diseases. Nevertheless, low design efficacy, time consumption, and high cost still hinder peptide drug design and ...
Ting Wei   +13 more
wiley   +1 more source

Home - About - Disclaimer - Privacy